SynthesisAnnals of the rheumatic diseases2013

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.